Vyome Partners With Impetis, a TATA Enterprise, to In‑License Next‑Generation JAK Inhibitors, Unlocking a ~$57B Global Market Opportunity Vyome has signed a landmark agreement with Impetis Biosciences, a TATA Enterprise, to in‑license two highly selective JAK inhibitor assets, opening access to a large and expanding ~$57 billion global market. These next‑generation inhibitors are engineered for…
